Albert Dme Osterhaus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5302777/publications.pdf

Version: 2024-02-01

265 papers 30,937 citations

70 h-index

11651

4885

303 all docs

303 docs citations

303 times ranked

28971 citing authors

168

g-index

#	Article	IF	CITATIONS
1	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. Science Immunology, 2022, 7, eabp9312.	11.9	35
2	Cross-reactive immunity potentially drives global oscillation and opposed alternation patterns of seasonal influenza A viruses. Scientific Reports, 2022, 12, .	3.3	2
3	TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 759-772.	3.3	1
4	COVID-19 vaccination and critical care capacity: Perilous months ahead. Vaccine, 2021, 39, 2183-2186.	3.8	2
5	Discrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs. Frontiers in Medicine, 2021, 8, 749588.	2.6	17
6	Hemagglutinin Traits Determine Transmission of Avian A/H10N7 Influenza Virus between Mammals. Cell Host and Microbe, 2020, 28, 602-613.e7.	11.0	20
7	Pandemic preparedness planning in peacetime: what is missing?. One Health Outlook, 2020, 2, 19.	3.4	3
8	Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. Blood Advances, 2020, 4, 2967-2978.	5.2	45
9	Mannitol treatment is not effective in therapy of rabies virus infection in mice. Vaccine, 2019, 37, 4710-4714.	3.8	7
10	Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza and Other Respiratory Viruses, 2018, 12, 267-278.	3.4	73
11	Transmission of morbilliviruses within and among marine mammal species. Current Opinion in Virology, 2018, 28, 133-141.	5.4	32
12	Virus detection in high-throughput sequencing data without a reference genome of the host. Infection, Genetics and Evolution, 2018, 66, 180-187.	2.3	9
13	Comparison of Different In Situ Hybridization Techniques for the Detection of Various RNA and DNA Viruses. Viruses, 2018, 10, 384.	3.3	21
14	Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model. Viruses, 2018, 10, 18.	3.3	7
15	Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 155-164.	1.6	10
16	Hyperferritinemia is a potential marker of chronic chikungunya: A retrospective study on the Island of Curaçao during the 2014–2015 outbreak. Journal of Clinical Virology, 2017, 86, 31-38.	3.1	22
17	AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?. Vaccine, 2017, 35, 4470-4474.	3.8	109
18	Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine, 2017, 35, 5095-5101.	3.8	84

#	Article	IF	CITATIONS
19	In Vitro and in Vivo Evaluation of Mutations in the NS Region of Lineage 2 West Nile Virus Associated with Neuroinvasiveness in a Mammalian Model. Viruses, 2016, 8, 49.	3.3	12
20	Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. Viruses, 2016, 8, 168.	3.3	42
21	Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. Journal of Medical Virology, 2016, 88, 1035-1043.	5.0	16
22	Influenza: from zoonosis to pandemic. ERJ Open Research, 2016, 2, 00013-2016.	2.6	25
23	Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness. Disaster Medicine and Public Health Preparedness, 2016, 10, 644-648.	1.3	7
24	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016, 12, 1-18.	3.3	49
25	Periodic global One Health threats update. One Health, 2016, 2, 1-7.	3.4	11
26	Vector-based genetically modified vaccines: Exploiting Jenner's legacy. Vaccine, 2016, 34, 6436-6448.	3.8	48
27	Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Vaccine, 2016, 34, 1915-1926.	3.8	16
28	Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infectious Diseases, 2015, 15, 371.	2.9	31
29	Susceptibility of Carrion Crows to Experimental Infection with Lineage $1\mathrm{and}2$ West Nile Viruses. Emerging Infectious Diseases, 2015, 21, 1357-1365.	4.3	31
30	Avian Influenza A(H10N7) Virus–Associated Mass Deaths among Harbor Seals. Emerging Infectious Diseases, 2015, 21, 720-722.	4.3	92
31	Virus characterization and discovery in formalin-fixed paraffin-embedded tissues. Journal of Virological Methods, 2015, 214, 54-59.	2.1	23
32	Pathogenesis of Infection with 2009 Pandemic H1N1 Influenza Virus in Isogenic Guinea Pigs after Intranasal or Intratracheal Inoculation. American Journal of Pathology, 2015, 185, 643-650.	3.8	13
33	Markers of endothelial cell activation and immune activation are increased in patients with severe leptospirosis and associated with disease severity. Journal of Infection, 2015, 71, 437-446.	3.3	17
34	Host-specific exposure and fatal neurologic disease in wild raptors from highly pathogenic avian influenza virus H5N1 during the 2006 outbreak in Germany. Veterinary Research, 2015, 46, 24.	3.0	34
35	Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. Journal of Virological Methods, 2015, 217, 55-63.	2.1	36
36	DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift. Vaccine, 2015, 33, 2922-2929.	3.8	10

3

#	Article	IF	Citations
37	Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus. Vaccine, 2015, 33, 6977-6982.	3.8	5
38	Pathogenicity and tissue tropism of currently circulating highly pathogenic avian influenza A virus (H5N1; clade 2.3.2) in tufted ducks (Aythya fuligula). Veterinary Microbiology, 2015, 180, 273-280.	1.9	9
39	Why should influenza be a public health priority?. Vaccine, 2015, 33, 7022-7025.	3.8	6
40	Dengue viruses cluster antigenically but not as discrete serotypes. Science, 2015, 349, 1338-1343.	12.6	195
41	Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis. Vaccine, 2015, 33, 4349-4358.	3.8	10
42	Quantifying the risk of pandemic influenza virus evolution by mutation and re-assortment. Vaccine, 2015, 33, 6955-6966.	3.8	24
43	Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro. Virus Research, 2015, 195, 43-46.	2.2	10
44	Susceptibility of Carrion Crows to Experimental Infection with Lineage 1 and 2 West Nile Viruses. Emerging Infectious Diseases, 2015, 21, 1357-1365.	4.3	25
45	Influenza from a One Health Perspective: Infection by a Highly Versatile Virus., 2015,, 455-486.		0
46	Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014. Emerging Infectious Diseases, 2014, 20, 1339-42.	4.3	164
47	Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine, 2014, 32, 5975-5982.	3.8	121
48	Experimental infection of highly pathogenic avian influenza virus H5N1 in black-headed gulls (Chroicocephalus ridibundus). Veterinary Research, 2014, 45, 84.	3.0	12
49	MERS: emergence of a novel human coronavirus. Current Opinion in Virology, 2014, 5, 58-62.	5.4	170
50	Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine, 2014, 32, 5614-5623.	3.8	13
51	Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. International Journal of Antimicrobial Agents, 2014, 44, 528-532.	2.5	103
52	Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets. BMC Microbiology, 2014, 14, 134.	3.3	30
53	Viral metagenomic analysis of feces of wild small carnivores. Virology Journal, 2014, 11, 89.	3.4	57
54	Intranasally administered Endocineâ,,¢ formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets. Vaccine, 2014, 32, 3307-3315.	3.8	15

#	Article	IF	Citations
55	Advances in influenza vaccination. F1000prime Reports, 2014, 6, 47.	5.9	18
56	Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable – epidemiology, diagnostics and treatment. Critical Reviews in Microbiology, 2013, 39, 26-42.	6.1	51
57	Molecular Assays for Quantitative and Qualitative Detection of Influenza Virus and Oseltamivir Resistance Mutations. Journal of Molecular Diagnostics, 2013, 15, 347-354.	2.8	32
58	Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infectious Diseases, The, 2013, 13, 859-866.	9.1	616
59	Virus discovery: one step beyond. Current Opinion in Virology, 2013, 3, e1-e6.	5.4	25
60	Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. Vaccine, 2013, 31, 6030-6033.	3.8	135
61	Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. Journal of Clinical Virology, 2013, 58, 629-634.	3.1	157
62	Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA. Journal of Virological Methods, 2013, 194, 146-153.	2.1	34
63	Influenza Virus Resistance to Antiviral Therapy. Advances in Pharmacology, 2013, 67, 217-246.	2.0	69
64	Novel Avian-Origin Influenza A (H7N9) Virus Attaches to Epithelium in Both Upper and Lower Respiratory Tract of Humans. American Journal of Pathology, 2013, 183, 1137-1143.	3.8	52
65	Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. Journal of Clinical Virology, 2013, 57, 215-221.	3.1	34
66	Age distribution of cases caused by different influenza viruses. Lancet Infectious Diseases, The, 2013, 13, 646-647.	9.1	10
67	Early divergence of Th1 and Th2 transcriptomes involves a small core response and sets of transiently expressed genes. European Journal of Immunology, 2013, 43, 1074-1084.	2.9	8
68	Paramyxovirus infections in ex vivo lung slice cultures of different host species. Journal of Virological Methods, 2013, 193, 159-165.	2.1	25
69	Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. Journal of Heart and Lung Transplantation, 2013, 32, 78-85.	0.6	63
70	Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 2578-2583.	3.3	1
71	Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections. Journal of Innate Immunity, 2013, 5, 197-208.	3.8	40
72	Recurring Influenza B Virus Infections in Seals. Emerging Infectious Diseases, 2013, 19, 511-512.	4.3	74

#	Article	IF	CITATIONS
73	Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011. Emerging Infectious Diseases, 2013, 19, .	4.3	72
74	Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets. PLoS Pathogens, 2013, 9, e1003343.	4.7	92
75	Emerging Viral Infections. , 2013, , 1142-1154.		2
76	Longitudinal study on oral shedding of herpes simplex virus 1 and varicella oster virus in individuals infected with HIV. Journal of Medical Virology, 2013, 85, 1669-1677.	5.0	37
77	Global Assessment of Resistance to Neuraminidase Inhibitors, 2008–2011: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, 2013, 56, 1197-1205.	5.8	93
78	Prevalence of phocine distemper virus specific antibodies: bracing for the next seal epizootic in north-western Europe. Emerging Microbes and Infections, 2013, 2, 1-5.	6.5	27
79	HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. Aids, 2013, 27, 2679-2689.	2.2	7
80	Pigs, Poultry, and Pandemic Influenza: How Zoonotic Pathogens Threaten Human Health. Advances in Experimental Medicine and Biology, 2012, 719, 59-66.	1.6	28
81	Influenza viruses. Human Vaccines and Immunotherapeutics, 2012, 8, 7-16.	3.3	35
82	Rinderpest eradication: lessons for measles eradication?. Current Opinion in Virology, 2012, 2, 330-334.	5.4	42
83	Systemic varicella zoster virus reactive effector memory Tâ€cells impaired in the elderly and in kidney transplant recipients. Journal of Medical Virology, 2012, 84, 2018-2025.	5.0	26
84	Annual influenza vaccination affects the development of heterosubtypic immunity. Vaccine, 2012, 30, 7407-7410.	3.8	35
85	The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D. Virus Research, 2012, 169, 301-305.	2.2	17
86	Adaptive pathways of zoonotic influenza viruses: From exposure to establishment in humans. Vaccine, 2012, 30, 4419-4434.	3.8	109
87	Evaluation of synthetic infection-enhancing lipopeptides as adjuvants for a live-attenuated canine distemper virus vaccine administered intra-nasally to ferrets. Vaccine, 2012, 30, 5073-5080.	3.8	8
88	Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. Journal of Clinical Virology, 2012, 53, 38-42.	3.1	48
89	Pediatric influenza vaccination: understanding the T-cell response. Expert Review of Vaccines, 2012, 11, 963-971.	4.4	13
90	Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model. Vaccine, 2012, 30, 7391-7394.	3.8	10

#	Article	IF	Citations
91	Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England Journal of Medicine, 2012, 367, 1814-1820.	27.0	4,688
92	Influenza A and B Virus Attachment to Respiratory Tract in Marine Mammals. Emerging Infectious Diseases, 2012, 18, 817-820.	4.3	20
93	Hepatitis E Virus Infection among Solid Organ Transplant Recipients, the Netherlands. Emerging Infectious Diseases, 2012, 18, 869-872.	4.3	135
94	Picobirnaviruses in the Human Respiratory Tract. Emerging Infectious Diseases, 2012, 18, 1538-1539.	4.3	33
95	Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh. Emerging Infectious Diseases, 2012, 18, 1192-1195.	4.3	28
96	Novel Hepatitis E Virus in Ferrets, the Netherlands. Emerging Infectious Diseases, 2012, 18, 1369-1370.	4.3	158
97	A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clinical Immunology, 2012, 142, 252-268.	3.2	93
98	Current and future applications of dried blood spots in viral disease management. Antiviral Research, 2012, 93, 309-321.	4.1	115
99	ISCOM technology-based Matrix Mâ,,¢ adjuvant: success in future vaccines relies on formulation. Expert Review of Vaccines, 2011, 10, 401-403.	4.4	128
100	Pathogenesis of Influenza A/H5N1 Virus Infection in Ferrets Differs between Intranasal and Intratracheal Routes of Inoculation. American Journal of Pathology, 2011, 179, 30-36.	3.8	95
101	Comprehensive analysis of the intracellular metabolism of antiretroviral nucleosides and nucleotides using liquid chromatography–tandem mass spectrometry and method improvement by using ultra performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2772-2782.	2.3	19
102	Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in $na\tilde{A}$ ve ferrets. Vaccine, 2011, 29, 2120-2126.	3.8	23
103	Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine, 2011, 29, 2092-2099.	3.8	15
104	Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies. Vaccine, 2011, 29, 3424-3430.	3.8	21
105	Vaccination strategies to protect children against seasonal and pandemic influenza. Vaccine, 2011, 29, 7551-7553.	3.8	5
106	Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine, 2011, 29, 9265-9270.	3.8	13
107	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 2. Future Virology, 2011, 6, 1283-1288.	1.8	0
108	Current research on respiratory viral infections: XIII International Symposium on Respiratory Viral Infections: part 1. Future Virology, 2011, 6, 1155-1160.	1.8	0

#	Article	IF	CITATIONS
109	Accumulation features of trace elements in mass-stranded harbor seals (Phoca vitulina) in the North Sea coast in 2002: The body distribution and association with growth and nutrition status. Marine Pollution Bulletin, 2011, 62, 963-975.	5.0	21
110	Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009–2010. Antiviral Research, 2011, 92, 81-89.	4.1	32
111	The ins and outs of universal childhood influenza vaccination. Future Microbiology, 2011, 6, 1171-1184.	2.0	8
112	Possible Increased Pathogenicity of Pandemic (H1N1) 2009 Influenza Virus upon Reassortment. Emerging Infectious Diseases, 2011, 17, 200-208.	4.3	67
113	Genogroup I and II Picobirnaviruses in Respiratory Tracts of Pigs. Emerging Infectious Diseases, 2011, 17, 2328-2330.	4.3	39
114	Towards universal influenza vaccines?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2766-2773.	4.0	51
115	West Nile Virus: Immunity and Pathogenesis. Viruses, 2011, 3, 811-828.	3.3	91
116	Wild Birds and Increased Transmission of Highly Pathogenic Avian Influenza (H5N1) among Poultry, Thailand. Emerging Infectious Diseases, 2011, 17, 1016-1022.	4.3	33
117	Quantitative proteome profiling of respiratory virus-infected lung epithelial cells. Journal of Proteomics, 2010, 73, 1680-1693.	2.4	48
118	Pandemics: is hoping for the best enough?. EMBO Reports, 2010, 11, 142-142.	4.5	2
119	Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Review of Vaccines, 2010, 9, 59-72.	4.4	85
120	Targets for the Induction of Protective Immunity Against Influenza A Viruses. Viruses, 2010, 2, 166-188.	3.3	12
121	Experimental Pandemic (H1N1) 2009 Virus Infection of Cats. Emerging Infectious Diseases, 2010, 16, 1745-1747.	4.3	32
122	A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virology Journal, 2010, 7, 146.	3.4	85
123	No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis. Journal of Clinical Virology, 2010, 49, 26-31.	3.1	39
124	Report of the fourth meeting on †Influenza vaccines that induce broad spectrum and long-lasting immune responses', World Health Organization and Wellcome Trust, London, United Kingdom, 9–10 November 2009. Vaccine, 2010, 28, 3875-3882.	3.8	22
125	Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine. Vaccine, 2010, 28, 4970-4976.	3.8	5
126	Seasonal and Pandemic Human Influenza Viruses Attach Better to Human Upper Respiratory Tract Epithelium than Avian Influenza Viruses. American Journal of Pathology, 2010, 176, 1614-1618.	3.8	146

#	Article	IF	CITATIONS
127	Highly Pathogenic Avian Influenza Virus H7N7 Isolated From a Fatal Human Case Causes Respiratory Disease in Cats but Does Not Spread Systemically. American Journal of Pathology, 2010, 177, 2185-2190.	3.8	33
128	SARS., 2009,, 671-683.		2
129	Response to Imported Case of Marburg Hemorrhagic Fever, the Netherlands. Emerging Infectious Diseases, 2009, 15, 1171-1175.	4.3	165
130	Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus–infected mice. Journal of Experimental Medicine, 2009, 206, 2339-2349.	8.5	311
131	Unraveling the complexities of the interferon response during SARS-CoV infection. Future Virology, 2009, 4, 71-78.	1.8	15
132	Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin, 2009, 5, 126-135.	2.4	41
133	Effects of influenza A virus infection on migrating mallard ducks. Proceedings of the Royal Society B: Biological Sciences, 2009, 276, 1029-1036.	2.6	174
134	Stage-structured transmission of phocine distemper virus in the Dutch 2002 outbreak. Proceedings of the Royal Society B: Biological Sciences, 2009, 276, 2469-2476.	2.6	35
135	On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals, 2009, 37, 216-221.	1.4	62
136	"Filoviruses― a real pandemic threat?. EMBO Molecular Medicine, 2009, 1, 10-18.	6.9	14
137	Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine, 2009, 27, 6363-6365.	3.8	58
138	Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag. Vaccine, 2009, 27, 5735-5739.	3.8	12
139	RNA secondary structures in the proximal $3\hat{a} \in 2$ UTR of Indonesian Dengue 1 virus strains. Virus Research, 2009, 142, 213-216.	2.2	5
140	Preparing the outbreak assistance laboratory network in the Netherlands for the detection of the influenza virus A(H1N1) variant. Journal of Clinical Virology, 2009, 45, 179-184.	3.1	26
141	The Application of Genomics to Emerging Zoonotic Viral Diseases. PLoS Pathogens, 2009, 5, e1000557.	4.7	49
142	Measles vaccination: new strategies and formulations. Expert Review of Vaccines, 2008, 7, 1215-1223.	4.4	23
143	Virogenomics: the virus–host interaction revisited. Current Opinion in Microbiology, 2008, 11, 461-466.	5.1	7
144	Association between high nasopharyngeal viral load and disease severity in children with human metapneumovirus infection. Journal of Clinical Virology, 2008, 42, 286-290.	3.1	53

#	Article	IF	Citations
145	Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine, 2008, 26, 153-157.	3.8	60
146	Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats. Vaccine, 2008, 26, 2553-2561.	3.8	3
147	Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine, 2008, 26, 3735-3741.	3.8	27
148	Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine, 2008, 26, 4224-4230.	3.8	45
149	Vaccines against seasonal and avian influenza: Recent advances. Vaccine, 2008, 26, D1-D2.	3.8	8
150	Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine, 2008, 26, D31-D34.	3.8	208
151	Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA. Veterinary Immunology and Immunopathology, 2008, 126, 332-338.	1.2	3
152	DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α. Virus Research, 2008, 135, 64-71.	2.2	62
153	Intrahost evolution of envelope glycoprotein and OrfA sequences after experimental infection of cats with a molecular clone and a biological isolate of feline immunodeficiency virus. Virus Research, 2008, 137, 24-32.	2.2	9
154	Clearance of influenza virus from the lung depends on migratory langerin+CD11bâ^ but not plasmacytoid dendritic cells. Journal of Experimental Medicine, 2008, 205, 1621-1634.	8.5	419
155	CCR5-Restricted HIV Type 2 Variants from Long-Term Aviremic Individuals Are Less Sensitive to Inhibition byβ-Chemokines Than Low Pathogenic HIV Type 1 Variants. AIDS Research and Human Retroviruses, 2008, 24, 473-484.	1.1	4
156	Wild Ducks as Long-Distance Vectors of Highly Pathogenic Avian Influenza Virus (H5N1). Emerging Infectious Diseases, 2008, 14, 600-607.	4.3	374
157	Epidemiology of Avian Influenza. Monographs in Virology, 2008, , 1-10.	0.6	10
158	New Respiratory Viruses of Humans. Pediatric Infectious Disease Journal, 2008, 27, S71-S74.	2.0	13
159	Appendix: Representative Compounds with Inhibitory Activity Against SARS CoV or Other CoVs in vitro. , 2008, , 255-256.		0
160	Colour Plate., 2008,, I-IV.		0
161	Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine. PLoS ONE, 2008, 3, e1401.	2.5	148
162	Highly Pathogenic Avian Influenza Virus (H5N1) Infection in Red Foxes Fed Infected Bird Carcasses. Emerging Infectious Diseases, 2008, 14, 1835-1841.	4.3	66

#	Article	IF	Citations
163	Severe acute respiratory syndrome (SARS) vaccines. , 2008, , 1301-1306.		O
164	Measles vaccination of macaques by dry powder inhalation. Vaccine, 2007, 25, 1183-1190.	3.8	55
165	Efficacy of a live attenuated tetravalent candidate dengue vaccine in na \tilde{A} ve and previously infected cynomolgus macaques. Vaccine, 2007, 25, 5409-5416.	3.8	31
166	Pre- or post-pandemic influenza vaccine?. Vaccine, 2007, 25, 4983-4984.	3.8	34
167	Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine, 2007, 25, 8518-8528.	3.8	51
168	An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells. Virus Research, 2007, 126, 282-287.	2.2	15
169	Attachment of infectious influenza A viruses of various subtypes to live mammalian and avian cells as measured by flow cytometry. Virus Research, 2007, 129, 175-181.	2.2	33
170	Coronavirus HKU1 in an Italian pre-term infant with bronchiolitis. Journal of Clinical Virology, 2007, 38, 251-253.	3.1	23
171	Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine, 2007, 25, 3800-3808.	3.8	36
172	Human and Avian Influenza Viruses Target Different Cells in the Lower Respiratory Tract of Humans and Other Mammals. American Journal of Pathology, 2007, 171, 1215-1223.	3.8	473
173	Surveillance of Influenza Virus A in Migratory Waterfowl in Northern Europe. Emerging Infectious Diseases, 2007, 13, 404-411.	4.3	214
174	Genetic Characterization of HPAI (H5N1) Viruses from Poultry and Wild Vultures, Burkina Faso. Emerging Infectious Diseases, 2007, 13, 611-613.	4.3	47
175	Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Current Opinion in Biotechnology, 2007, 18, 529-536.	6.6	111
176	Characterization of humoral and cellular immune responses in cynomolgus macaques upon primary and subsequent heterologous infections with dengue viruses. Microbes and Infection, 2007, 9, 940-946.	1.9	38
177	Validation of an HIV-1 inactivation protocol that is compatible with intracellular drug analysis by mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 38-44.	2.3	11
178	Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infectious Diseases, 2007, 7, 22.	2.9	31
179	Rapid sequencing of the non-coding regions of influenza A virus. Journal of Virological Methods, 2007, 139, 85-89.	2.1	24
180	An improved plaque reduction virus neutralization assay for human metapneumovirus. Journal of Virological Methods, 2007, 143, 169-174.	2.1	41

#	Article	IF	CITATIONS
181	In vitro and in vivo replication of seal gammaherpesviruses in cells of multiple species. Microbes and Infection, 2007, 9, 40-46.	1.9	4
182	Influenza A Virus (H5N1) Infection in Cats Causes Systemic Disease with Potential Novel Routes of Virus Spread within and between Hosts. American Journal of Pathology, 2006, 168, 176-183.	3.8	252
183	T Cell Responses to Respiratory Syncytial Virus Fusion and Attachment Proteins in Human Peripheral Blood Mononuclear Cells. Viral Immunology, 2006, 19, 669-678.	1.3	8
184	Characterization of the varicella zoster virus (VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis. Experimental Eye Research, 2006, 83, 69-75.	2.6	16
185	High prevalence of influenza A virus in ducks caught during spring migration through Sweden. Vaccine, 2006, 24, 6734-6735.	3.8	25
186	Towards improved influenza A virus surveillance in migrating birds. Vaccine, 2006, 24, 6729-6733.	3.8	64
187	Aerosol measles vaccination in macaques: Preclinical studies of immune responses and safety. Vaccine, 2006, 24, 6424-6436.	3.8	34
188	Evidence for specific packaging of the influenza A virus genome from conditionally defective virus particles lacking a polymerase gene. Vaccine, 2006, 24, 6647-6650.	3.8	29
189	Mounting evidence for the presence of influenza A virus in the avifauna of the Antarctic region. Antarctic Science, 2006, 18, 353-356.	0.9	36
190	Feline friend or potential foe?. Nature, 2006, 440, 741-742.	27.8	42
190	Feline friend or potential foe?. Nature, 2006, 440, 741-742. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154.	27.8 2.4	42
	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353,		
191	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154. Interferon-Î ³ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in	2.4	34
191 192	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481.	2.4	120
191 192 193	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481. Coronaviruses and their therapy. Antiviral Research, 2006, 71, 397-403. Impact of human coronavirus infections in otherwise healthy children who attended an emergency	2.4	34 120 47
191 192 193	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481. Coronaviruses and their therapy. Antiviral Research, 2006, 71, 397-403. Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. Journal of Medical Virology, 2006, 78, 1609-1615. Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human	2.4 2.4 4.1 5.0	34 120 47 79
191 192 193 194	In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology, 2006, 353, 144-154. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology, 2006, 353, 474-481. Coronaviruses and their therapy. Antiviral Research, 2006, 71, 397-403. Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. Journal of Medical Virology, 2006, 78, 1609-1615. Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human coronaviruses. Current Opinion in Infectious Diseases, 2005, 18, 141-146.	2.4 2.4 4.1 5.0	34 120 47 79

#	Article	IF	CITATIONS
199	Phocine Distemper Outbreak, the Netherlands, 2002. Emerging Infectious Diseases, 2005, 11, 1945-1948.	4.3	21
200	Mallards and Highly Pathogenic Avian Influenza Ancestral Viruses, Northern Europe. Emerging Infectious Diseases, 2005, 11, 1545-1551.	4.3	187
201	Acquisition and Clearance of Perianal Human Papillomavirus Infection in Relation to HIVâ€positivity in Men Who Have Sex with Men in the Netherlands. Acta Dermato-Venereologica, 2005, 85, 437-443.	1.3	12
202	HIV and Smallpox. Science, 2005, 308, 1258b-1259b.	12.6	0
203	A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine, 2005, 23, 1657-1667.	3.8	79
204	Highly pathogenic avian influenza (H7N7): Vaccination of zoo birds and transmission to non-poultry species. Vaccine, 2005, 23, 5743-5750.	3.8	43
205	Antigenic and Genetic Variability of Human Metapneumoviruses. Emerging Infectious Diseases, 2004, 10, 658-666.	4.3	329
206	Respiratory Picornaviruses and Respiratory Syncytial Virus as Causative Agents of Acute Expiratory Wheezing in Children. Emerging Infectious Diseases, 2004, 10, 1095-1101.	4.3	298
207	Avian Influenza H5N1 in Tigers and Leopards. Emerging Infectious Diseases, 2004, 10, 2189-2191.	4.3	405
208	Elevation of soluble VCAM-1 plasma levels in children with acute dengue virus infection of varying severity. Journal of Medical Virology, 2004, 72, 445-450.	5.0	52
209	Human herpes simplex virus keratitis: the pathogenesis revisited. Ocular Immunology and Inflammation, 2004, 12, 255-285.	1.8	77
210	Avian H5N1 Influenza in Cats. Science, 2004, 306, 241-241.	12.6	374
211	Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Research, 2004, 103, 155-161.	2.2	171
212	Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine, 2004, 22, 915-922.	3.8	45
213	Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine, 2004, 22, 923-926.	3.8	32
214	An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine, 2004, 22, 3035-3044.	3.8	69
215	Does influenza vaccination exacerbate asthma in children?. Vaccine, 2004, 23, 91-96.	3.8	28
216	Experimental Human Metapneumovirus Infection of Cynomolgus Macaques (Macaca fascicularis) Results in Virus Replication in Ciliated Epithelial Cells and Pneumocytes with Associated Lesions throughout the Respiratory Tract. American Journal of Pathology, 2004, 164, 1893-1900.	3.8	145

#	Article	IF	Citations
217	Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. Journal of Clinical Virology, 2004, 29, 92-94.	3.1	49
218	Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet, The, 2004, 363, 587-593.	13.7	731
219	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet, The, 2004, 363, 2139-2141.	13.7	252
220	Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice Blood, 2004, 104, 47-47.	1.4	1
221	Emerging viral infections in a rapidly changing world. Current Opinion in Biotechnology, 2003, 14, 641-646.	6.6	71
222	Comparative study of different methods to genotype hepatitis C virus type 6 variants. Journal of Virological Methods, 2003, 109, 195-201.	2.1	56
223	Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. Journal of Medical Virology, 2003, 70, 91-98.	5.0	64
224	RSV-induced bronchiolitis but not upper respiratory tract infection is accompanied by an increased nasal IL-18 response. Journal of Medical Virology, 2003, 71, 290-297.	5.0	33
225	Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins. Microbes and Infection, 2003, 5, 379-385.	1.9	16
226	Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatric Allergy and Immunology, 2003, 14, 363-370.	2.6	119
227	The Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 349, 2431-2441.	27.0	1,133
228	Human metapneumovirus in the community. Lancet, The, 2003, 361, 890-891.	13.7	104
229	Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, The, 2003, 362, 263-270.	13.7	956
230	Immunogenicity and efficacy of recombinant subunit vaccines against phocid herpesvirus type 1. Vaccine, 2003, 21, 2433-2440.	3.8	6
231	Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976.	27.0	3,971
232	Vaccination against measles: a neverending story. Expert Review of Vaccines, 2002, 1, 151-159.	4.4	27
233	Metapneumovirus and acute wheezing in children. Lancet, The, 2002, 360, 1393-1394.	13.7	271
234	The choice of antigen for therapeutic immunization against AIDS. Trends in Immunology, 2002, 23, 478-479.	6.8	7

#	Article	IF	Citations
235	Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination. Vaccine, 2002, 20, 2022-2026.	3.8	22
236	DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine, 2002, 20, 2045-2052.	3.8	18
237	The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine, 2002, 20, 2011-2015.	3.8	42
238	Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates. Vaccine, 2002, 21, 155-157.	3.8	14
239	$V\hat{l}^39V\hat{l}^2$ T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens. Journal of Neuroimmunology, 2002, 130, 46-54.	2.3	49
240	Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef. Journal of Virological Methods, 2002, 99, 115-121.	2.1	5
241	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	4.1	43
242	Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes and Infection, 2002, 4, 1209-1215.	1.9	110
243	Analysis of the Genomic Sequence of a Human Metapneumovirus. Virology, 2002, 295, 119-132.	2.4	382
244	Another Phocine Distemper Outbreak in Europe. Science, 2002, 297, 209-209.	12.6	138
245	Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine, 2001, 19, 3700-3709.	3.8	161
246	In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine, 2001, 20, 249-261.	3.8	10
247	A candidate phocid herpesvirus vaccine that provides protection against feline herpesvirus infection. Vaccine, 2001, 20, 943-948.	3.8	7
248	Antigen Loading of MHC Class I Molecules in the Endocytic Tract. Traffic, 2001, 2, 124-137.	2.7	91
249	A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Medicine, 2001, 7, 719-724.	30.7	1,821
250	Catastrophes after crossing species barriers. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 791-793.	4.0	55
251	Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology, 2000, 61, 94-99.	5.0	200
252	Transgenic Mice Expressing Human HLA and CD8 Molecules Generate HLA-Restricted Measles Virus Cytotoxic T Lymphocytes of the Same Specificity as Humans with Natural Measles Virus Infection. Virology, 2000, 275, 286-293.	2.4	18

#	Article	IF	CITATIONS
253	Mass Die-Off of Caspian Seals Caused by Canine Distemper Virus. Emerging Infectious Diseases, 2000, 6, 637-639.	4.3	178
254	In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine, 2000, 18, 2482-2493.	3.8	27
255	Use of cotton rats for preclinical evaluation of measles vaccines. Vaccine, 2000, 19, 42-53.	3.8	35
256	Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly., 2000, 61, 94.		1
257	Integration of Vitamin A Supplementation with the Expanded Program on Immunization Does Not Affect Seroconversion to Oral Poliovirus Vaccine in Infants. Journal of Nutrition, 1999, 129, 2203-2205.	2.9	26
258	New clues to the emergence of flu pandemics. Nature Medicine, 1998, 4, 1122-1123.	30.7	23
259	Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. Journal of Virological Methods, 1998, 71, 35-44.	2.1	35
260	Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, The, 1998, 351, 472-477.	13.7	1,266
261	Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine, 1998, 16, 1479-1481.	3.8	36
262	Canine distemper virus — A morbillivirus in search of new hosts?. Trends in Microbiology, 1997, 5, 120-124.	7.7	127
263	Morbillivirus in monk seal mass mortality. Nature, 1997, 388, 838-839.	27.8	78
264	A determinant of feline immunodeficiency virus involved in Crandell feline kidney cell tropism. Veterinary Immunology and Immunopathology, 1995, 46, 61-69.	1.2	48
265	Relative immunocompetence of the newborn harbour seal, Phoca vitulina. Veterinary Immunology and Immunopathology, 1994, 42, 331-348.	1.2	70